Drug intelligence / Profile preview

BG-T187

Development stage
Phase 1
Lead developer
BeOne Medicines
Modality
Vaccines & Immunotherapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

BG-T187 is a trispecific antibody developed by BeiGene for the treatment of advanced solid tumors, including lung cancer and gastrointestinal neoplasms. It targets both the epidermal growth factor receptor (EGFR) and c-Met (hepatocyte growth factor receptor), functioning as an EGFR antagonist and c-Met inhibitor. The drug is designed to block EGFR signaling, inhibit c-Met activity, stimulate T lymphocytes, and induce antibody-dependent cell cytotoxicity. As of early 2025, BG-T187 is in Phase 1 clinical trials as both monotherapy and in combination with other agents for patients with advanced or metastatic solid tumors[1][2][3][4][5][6][8].

Other names
anti-EGFR×c-MET×c-MET trispecific antibodyEGFR x MET x MET trispecific antibody
02

Targets

EGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on BG-T187.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG-T187.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call